Role of Intranasal Topical Steroid in Pediatric Sleep Disordered Breathing and Influence of Allergy, Sinusitis, and Obesity on Treatment Outcome

• Main Authors: Yong Gi Jung, Hyo Yeol Kim, Jin-Young Min, Hun-Jong Dhong, Seung-Kyu Chung
• Format: Article
• Language: English
• Published: Korean Society of Otorhinolaryngology-Head and Neck Surgery 2011-03-01
• Series: Clinical and Experimental Otorhinolaryngology
• Subjects: Steroid; Topical administration; Sleep disorder; Adenoid; Pediatrics; Allergy
• Online Access: http://www.e-ceo.org/upload/pdf/ceo-4-27.pdf
• ISSN: 1976-8710; 2005-0720

ObjectivesTo evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleep-disordered breathing (SDB) patients.MethodsA prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. All patients received 4-weeks course of mometasone furoate 100 µg/day treatment. They were evaluated at pretreatment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment.ResultsTotal OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity (P=0.003, P=0.006). There was no complication after treatment of mometasone furoate.ConclusionPediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometasone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment.